Mankind Pharma, India’s fourth-largest pharmaceutical company, announced strong financial results for the second quarter of FY25, driven by growth across various segments and strategic expansions.
Key Financial Highlights (Consolidated):
- Revenue for Q2 FY25 rose by 14% year-on-year to ₹3,077 crore, supported by robust performance in the domestic market and strong export growth. Domestic revenue accounted for ₹2,796 crore (up 11% YoY), while exports stood at ₹281 crore, reflecting a 57% YoY increase.
- EBITDA surged by 24% YoY to ₹853 crore, with an EBITDA margin of 27.7%.
- Profit After Tax (PAT) increased by 29% YoY, reaching ₹659 crore. The PAT margin stood at 21.4%.
H1 FY25 Performance Overview: For the first half of FY25, Mankind Pharma reported a revenue of ₹5,970 crore, marking a 13% YoY growth. Adjusted EBITDA for H1 FY25 was ₹1,580 crore, up 17% YoY, with a margin of 26.5%. PAT for the half-year period rose 20% YoY to ₹1,202 crore.
Segment Highlights:
- Domestic Business: Mankind Pharma’s domestic market performance was strong, with secondary sales growing at 8.6% compared to the overall Indian Pharmaceutical Market (IPM) growth of 8.0%.
- Consumer Healthcare: The consumer healthcare segment saw a 20% YoY revenue growth in Q2 FY25, led by key brands like Manforce, Gas-O-Fast, and HealthOk.
- Exports: Export revenue soared by 57% YoY, fueled by new product launches and a stable base business. The company also introduced a new product in the U.S. market during the quarter.
Management Insights: Vice Chairman & Managing Director, Mr. Rajeev Juneja, attributed the company’s growth to strong operational leverage, resilient performance in the chronic segment, and strategic acquisitions, including BSV. He highlighted that the recent acquisition aligns with the company’s vision to enhance its specialty portfolio in critical care and gynaecology.
Outlook: Mankind Pharma’s diverse growth levers, spanning resilient base business, specialty segments, OTC products, and international expansion, place it on a robust path for sustained growth in the coming quarters.
